GlassScriptPhysician profile
Nidhi Kasatwar
NPI 1841673977
$6,674.51
in general payments reported to CMS, 2019-2025
41 companies · $2,711 in 2025
The $2,711 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.17 · 2022: $395 · 2023: $1,071 · 2024: $2,468 · 2025: $2,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,142 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,142.34 |
| Education | $107.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,447.79 | 2022-2025 | |
| Ucb, INC. | $782.67 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Celgene Corporation | $522.70 | 2023-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $452.69 | 2023-2025 | |
| Livanova USA, INC. | $440.47 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Pfizer INC. | $321.46 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $300.79 | 2023-2024 | Austedo Xr, Ajovy, Austedo |
| Tg Therapeutics, INC. | $236.42 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $224.93 | 2024-2025 | Hyqvia |
| Neurelis, INC. | $192.73 | 2024-2025 | Valtoco |
| Imperative Care, INC | $156.14 | 2022-2025 | Zoom 88-T Large Distal Platform |
| Janssen Pharmaceuticals, INC | $124.99 | 2023 | Xarelto |
| Biogen, INC. | $113.10 | 2025 | Vumerity, Leqembi, Tysabri |
| Acadia Pharmaceuticals INC | $108.86 | 2023-2025 | Nuplazid, Daybue |
| Octapharma USA, INC. | $100.00 | 2023-2025 | Panzyga |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $95.80 | 2022-2024 | |
| Csl Behring | $93.70 | 2024-2025 | Hizentra |
| Argenx US, INC. | $85.82 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Lundbeck LLC | $83.95 | 2024-2025 | Vyepti, Rexulti |
| Neuropace, INC. | $69.86 | 2024 | |
| Catalyst Pharmaceuticals, INC. | $63.25 | 2024 | |
| Lilly USA, LLC | $58.13 | 2024 | Amyvid, Kisunla, Emgality |
| Neurocrine Biosciences, INC. | $55.31 | 2024 | Ingrezza |
| Jazz Pharmaceuticals INC. | $54.79 | 2024 | |
| Amgen INC. | $49.53 | 2022-2025 | Uplizna |
| Sumitomo Pharma America, INC. | $46.49 | 2023-2024 | Aptiom |
| Emd Serono, INC. | $43.03 | 2024 | |
| Immedica Pharma US, INC. | $40.92 | 2022 | |
| Medtronic, INC. | $38.17 | 2024-2025 | Percept PC Brainsense |
| Azurity Pharmaceuticals, INC. | $35.51 | 2024 | Horizant |
| Ge Healthcare | $35.51 | 2024 | |
| Averitas Pharma INC. | $30.02 | 2023 | Qutenza |
| Vanda Pharmaceuticals INC. | $25.00 | 2025 | Ponvory |
| Grifols USA, LLC | $21.39 | 2025 | Gamunex-C |
| Boston Scientific Corporation | $20.67 | 2024 | |
| Davol INC. | $20.05 | 2023 | Avitene Ultrafoam |
| Genentech USA, INC. | $19.95 | 2024 | Ocrevus Zunovo, Ocrevus |
| Biohaven Pharmaceutical Holding Company LTD. | $19.77 | 2022 | |
| Impel Pharmaceuticals LLC | $14.26 | 2025 | Trudhesa |
| Axsome Therapeutics, INC. | $14.15 | 2025 | Symbravo |
| Aucta Pharmaceuticals, INC. | $13.74 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nidhi Kasatwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.